JPRN-UMIN000003076
Recruiting
Phase 2
Phase II study to evaluate the safety and the efficacy of CBD (Bortezomib, Cyclophosphamide, Dexamethasone) regimen for the patients with relapsed and/or refractory multiple myeloma - Phase II study to evaluate the safety and the efficacy of CBD (Bortezomib, Cyclophosphamide, Dexamethasone) regimen for the patients with relapsed and/or refractory multiple myeloma
ara Hospital Kinki University School Of Medicine0 sites20 target enrollmentFebruary 1, 2010
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- relapsed and/or refractory multiple myeloma
- Sponsor
- ara Hospital Kinki University School Of Medicine
- Enrollment
- 20
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •performance status:3 and 4(excluding PS3 by bone pain and fracture)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Study of a combination therapy in patients with Waldenstrom Macroglobulinemia and active disease not previously treatedEUCTR2013-002388-25-ITAzienda Ospedaliera Ospedali Riuniti Marche Nord40
Recruiting
Phase 2
GCDR trialJPRN-jRCTs051230119Kitano Masayuki38
Recruiting
Phase 2
Evaluation of the efficacy of bioadhesive barrier-forming oral liquid gel (Episil) for prevention of oral mucositisJPRN-jRCTs062220023Takano HIdeyuki50
Completed
Not Applicable
Intensive blood glucose control for chronic obstructive pulmonary disease (COPD) patients on acute medical wardsAcute exacerbation of chronic obstructive pulmonary disease (AECOPD)RespiratoryOther chronic obstructive pulmonary diseaseISRCTN42412334St George's, University of London (UK)20
Not yet recruiting
Phase 2
Study to examine the efficacy and safety of Awa Suzuka extracted ingredientsHealthy subjects with serum triglyceride levels in the borderline rangeJPRN-UMIN000052759Tokushima University Graduate School40